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pr&xn of the ,tudy. ln the ISIS-3 drvg adm,mr,rat,on prolocol. 
paGents were given one active agent and one p[.xcho. The anis- 
~replaw iAPSACI !w IO be reconstituted and Ihe total contenls 
injected over 3 min Swcpwhinaw was administered as a constant 
unount of 1.5 million U. over I h by mtrweno~s infusion. Only the 
pat~cnls aivcn rt.PA required a weight estmmtion or determination. 
lhrn a weighl.adjuatcd do<e calculation, and formulation of Ihe 
appropnatc in~ri~vcnuub conccnlration to produce a totsI dose ofQ.6 
million Uikg body weight over 4 h 14). 
In none of the official ISIS-3 pre-enrollment data sheets. or the 
follow-up case reporting materials dent ID the dam monitoring 
wmmittcc wcrc tbc Patient5 weights. or the total dose of any ofthe 
apenw actually admi&tered. rep&ted. In this aludy, whichenrolled 
>4h.OnO oatients in 16 coumries. the fornulation of the rt-PA dose 
war the ;nly variable dosing arm. and introduced a source of error 
unique to that group. If the patients’ weights wcrc not accuralely 
dctelmincd. or the rt-PA not mixed correctly (i.e.. solution made up 
85 if the drug were alteplase. and not duteplasel. then patienta could 
have received enough drug for a 95 kg person. the maximal dose 
supplied. 
Wathoul rewcw of the dose administcrcd of a nonstandard drug. 
a dosing error cannot be ruled out as causing the excess of 
intracranial hemorrhage in Ihe rl-PA group,ascompsredloprevious 
studies. ‘Therefore. in all future studier the dose of the medication 
rcccivcd ix ihc test rubiects should be recorded for further analvsls 
and review. 
When the ISIS-? resulls are published it will be possible to discuss 
rhew inlerpretation in delail. In the meantime. il is interestingto note 
that in both LSIS-3 and GISSI.2 (1.2) there appeared to be no 
diffcrcnce at all in S-week mortality between patients allocated 
streptokinase (2,355 death% among 23.691 patients in both wdier 
combined: 9.9%) and Ihose allocated rt.F’A (2.361 death, among 
23.662; 10.0%1. Trsalmcnl with rl-PA was. however. associaled 
with a highly statistically ngmficam excess of stroke “01 just in 
Table 2. Timing of Any Stroke Among Patients Randomized to 
Streptokinase Versus n-PA in ISIS-3 and GISSI-2 (and its 
international extension) 
Day or,flrr:, 
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GISSI.2 
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Significance 
Level 
< 0.02 
< 0.002 
D.I 
NS 
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ISIS-3 but also in GISSI-2 (Table Il. In both studies this excess was 
equivalent to about 4 extra strokes per l.wO patients treated with 
GA and it appeared early aRer the start of treatment (Table 2). 
This excess tiak of strokes WP.S attributed in ISIS-3 ID cerebral 
hemorrhage (39 streptokinase IO.3951 vs. 94 &PA @X7%1; 2p < 
O.MMIl. which is not statislically inconsistent with thenonsignihcant 
excess ofcerebral hemorrhage reported in GISSI-2 (30 streprokinase 
[0.3%] vs. 44 CPA [0.4%]: 2p = 0.1). For mwtaliiy and for stroke. 
therefore. the results from lhese two large (and. hence, statistically 
reliable1 trials are entirely consislent with each other. 
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